Sandoz vs China: A Test Case for the EU's New Anti-Dumping Posture on Pharma Chemicals

The European pharmaceutical industry is closely watching a new trade development after Sandoz called on the European Commission to investigate imports of amoxicillin trihydrate from China. The company alleges that Chinese manufacturers have benefited from unfair state subsidies and have sold the antibiotic active ingredient at below-market prices, creating an uneven competitive environment.

If the European Commission proceeds with an anti-dumping investigation and eventually imposes trade measures, the decision could influence API pricing, supplier competition, and procurement strategies across Europe's pharmaceutical industry.

For API manufacturers, procurement professionals, and pharmaceutical companies, the case highlights the growing intersection between healthcare supply chains and international trade policy.

Why Amoxicillin Trihydrate Matters

Amoxicillin trihydrate is one of the world's most widely used antibiotic active pharmaceutical ingredients (APIs).

It is commonly used in the production of:

• Oral capsules

• Tablets

• Suspensions

• Pediatric formulations

• Combination antibiotic medicines

• Generic pharmaceutical products

Because of its widespread use, changes in API supply or pricing can affect manufacturers throughout the pharmaceutical sector.

Alongside Amoxicillin Trihydrate, pharmaceutical manufacturers rely on excipients and formulation ingredients such as Mannitol, Polyethylene Glycol (PEG), Propylene Glycol (USP Grade), Citric Acid, Sorbitol, and Glycerin to produce high-quality oral tablets, capsules, and liquid formulations. Reliable sourcing of these materials is essential for consistent pharmaceutical production.

Potential Impact of an Anti-Dumping Investigation

If trade measures are introduced, pharmaceutical manufacturers may experience several market changes.

Possible implications include:

• Higher import costs

• Greater demand for European API producers

• Supplier diversification

• Changes in procurement strategies

• Increased focus on supply chain resilience

• Long-term investment in regional manufacturing

The final market impact will depend on the outcome of the European Commission's investigation and any resulting policy decisions.

Procurement Considerations

Procurement teams should closely monitor developments throughout the investigation.

Key priorities include:

• Reviewing supplier exposure

• Evaluating alternative API sources

• Monitoring regulatory developments

• Assessing long-term contracts

• Strengthening supplier diversification

• Managing inventory strategically

Building a diversified supplier network can help reduce exposure to future trade policy changes.

Looking Ahead

The Sandoz case reflects a broader trend of increasing scrutiny over pharmaceutical supply chains and international trade practices. As governments place greater emphasis on medicine security and domestic manufacturing, anti-dumping investigations may become a more common feature of the pharmaceutical industry.

For procurement professionals, maintaining flexible sourcing strategies and monitoring regulatory developments will remain essential for ensuring long-term supply continuity.

Key Takeaways

• Sandoz has requested an EU investigation into Chinese amoxicillin trihydrate imports.

• The case focuses on allegations of unfair subsidies and below-market pricing.

• Any trade measures could influence API pricing and sourcing strategies.

• Procurement teams should diversify suppliers and monitor regulatory developments.

• Trade policy is becoming an increasingly important factor in pharmaceutical procurement.